Kaleido Biosciences Stock Profit Margin
KLDODelisted Stock | USD 0.01 0.00 0.00% |
Kaleido Biosciences fundamentals help investors to digest information that contributes to Kaleido Biosciences' financial success or failures. It also enables traders to predict the movement of Kaleido Pink Sheet. The fundamental analysis module provides a way to measure Kaleido Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kaleido Biosciences pink sheet.
Kaleido |
Kaleido Biosciences Company Profit Margin Analysis
Kaleido Biosciences' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, Kaleido Biosciences has a Profit Margin of 0.0%. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The profit margin for all United States stocks is 100.0% lower than that of the firm.
Kaleido Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kaleido Biosciences' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Kaleido Biosciences could also be used in its relative valuation, which is a method of valuing Kaleido Biosciences by comparing valuation metrics of similar companies.Kaleido Biosciences is currently under evaluation in profit margin category among its peers.
Kaleido Fundamentals
Return On Equity | -5.81 | ||||
Return On Asset | -1.0 | ||||
Operating Margin | (79.28) % | ||||
Current Valuation | (16.73 M) | ||||
Shares Outstanding | 42.62 M | ||||
Shares Owned By Insiders | 0.73 % | ||||
Shares Owned By Institutions | 0.36 % | ||||
Number Of Shares Shorted | 2.34 M | ||||
Price To Earning | (1.45) X | ||||
Price To Book | 0 X | ||||
Price To Sales | 0.04 X | ||||
Revenue | 1.1 M | ||||
Gross Profit | (66.7 M) | ||||
EBITDA | (85.09 M) | ||||
Net Income | (90.29 M) | ||||
Cash And Equivalents | 38.47 M | ||||
Cash Per Share | 0.90 X | ||||
Total Debt | 5.55 M | ||||
Debt To Equity | 2.04 % | ||||
Current Ratio | 1.42 X | ||||
Book Value Per Share | 0.25 X | ||||
Cash Flow From Operations | (77.09 M) | ||||
Short Ratio | 29.34 X | ||||
Earnings Per Share | (2.16) X | ||||
Target Price | 22.0 | ||||
Number Of Employees | 76 | ||||
Beta | 0.42 | ||||
Market Capitalization | 421.96 K | ||||
Total Asset | 50.14 M | ||||
Retained Earnings | (197.63 M) | ||||
Working Capital | 62.54 M | ||||
Current Asset | 72.93 M | ||||
Current Liabilities | 10.39 M | ||||
Z Score | -6.3 | ||||
Net Asset | 50.14 M |
About Kaleido Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kaleido Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kaleido Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kaleido Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Kaleido Pink Sheet
If you are still planning to invest in Kaleido Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kaleido Biosciences' history and understand the potential risks before investing.
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |